Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, is a a valuable research substance extensively used in cardiovascular studies . This Fab fragment selectively targets the glycoprotein IIb/IIIa receptor on blood cells, inhibiting thrombus development. Therefore , it's commonly employed as a tool to examine the pathways underlying coagulation and to determine the effectiveness of antiplatelet medications . Supply is typically restricted to research settings.
```
Abciximab Drug Research: Utilizing C7E3 Antibody and The 143653-53-6 Substance in Studies
Ongoing investigation into abciximab, a antiplatelet agent, frequently incorporates the here monoclonal antigen C7E3 and the chemical compound identified as 143653-53-6. These reagents are crucial for examining abciximab's mechanism of action, evaluating its therapeutic effect in various clinical settings, and exploring potential indicators of patient outcome. Continued exploration leveraging these particular reagents is expected to generate valuable information for enhancing patient care concerning cardiovascular conditions.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Exploring Research Possibilities with this Glycoprotein IIb/IIIa Inhibitor 143653-53-6 and C7E3
Recent studies indicate that the drug (identified as 143653-53-6) holds significant scientific value, particularly when combined with the antibody fragment. Early observations have that this association could boost clinical outcomes in various arterial contexts. Further exploration is directed on elucidating the precise mechanism of interaction between the antiplatelet medication and C7E3, involving assessment of platelet clumping and blood vessel preservation.
- Current investigation work seek to refine dosing approaches.
- Animal models are being utilized to further assess these hypotheses.
- Human studies might be necessary to thoroughly assess patient benefit.
```
Abciximab (C7E3) for Research: Purity and Details (143653-53-6)
Researchers requiring abciximab for in vitro research should carefully consider purity and precise characteristics. The compound is typically supplied as a freeze-dried powder and comprehensive analytical information including identity by LC-MS, potency assays, and bacterial endotoxin testing is available. Confirm the manufacturer's CoA clearly states acceptable limits for contaminants and conforms to all quality control standards .
Research-Grade ReoPro Details & Availability
Acquiring laboratory-grade Abciximab, specifically referencing the antibody C7E3 and identified by the product number 143653-53-6, requires thorough consideration of its source . This glycoprotein is frequently utilized in cell-based studies , particularly those focused on platelet adhesion and occlusion. Available sources offer this material in varying volumes, typically ranging from milligram to significant bulk amounts . We advise reviewing the documentation of testing to verify quality and appropriateness for your specific purpose. Furthermore , confirm the stability date before procuring to maintain ideal effectiveness.
- Common Purity: >95%
- Storage Conditions: -20°C and suitable conditions
- Intended Purpose: Platelet Adhesion Blocking Studies
Comments on “```text”